• LAST PRICE
    0.3200
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-13.5135%)
  • Bid / Lots
    0.3200/ 247
  • Ask / Lots
    0.3693/ 25
  • Open / Previous Close
    0.3693 / 0.3700
  • Day Range
    Low 0.3200
    High 0.3693
  • 52 Week Range
    Low 0.3000
    High 38.0000
  • Volume
    581
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.3693
TimeVolumePBLA
09:42 ET1040.34465
01:51 ET1500.32
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPBLA
Panbela Therapeutics Inc
1.8M
0.0x
---
United StatesKRBP
Kiromic Biopharma Inc
1.7M
-0.1x
---
United StatesZVSA
Zyversa Therapeutics Inc
1.9M
0.0x
---
United StatesDRMA
Dermata Therapeutics Inc
1.8M
-0.1x
---
United StatesPHBI
Pharmagreen Biotech Inc
1.7M
-3.0x
---
United StatesAGTX
Agentix Corp
2.0M
-6.1x
---
As of 2024-11-05

Company Information

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

Contact Information

Headquarters
712 Vista Blvd # 305WACONIA, MN, United States 55387
Phone
952-479-1196
Fax
---

Executives

Chairman of the Board
Michael Cullen
President, Chief Executive Officer, Director
Jennifer Simpson
Lead Independent Vice Chairman of the Board
Jeffrey Mathiesen
Chief Financial Officer, Vice President - Finance, Treasurer, Company Secretary
Susan Horvath
Director
Jeffrey Jacob

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.8M
Revenue (TTM)
$0.00
Shares Outstanding
4.9M
Panbela Therapeutics Inc does not pay a dividend.
Beta
0.96
EPS
$-84.64
Book Value
$-9.81
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.